High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$398K
$398,749
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| NKTR |
NEKTAR THERAPEUTICS
|
CEO
Sell to Cover
|
2026-02-18 | $30,879 | S | Form 4 |
|
NKTR
S
NEKTAR THERAPEUTICS
Zalevsky Jonathan
• Officer • Chief R&D Officer
Sell to Cover
2026-02-18
$13,140
|
||||||
| NKTR |
NEKTAR THERAPEUTICS
|
Officer • Chief R&D Officer
Sell to Cover
|
2026-02-18 | $13,140 | S | Form 4 |
|
NKTR
S
NEKTAR THERAPEUTICS
Zalevsky Jonathan
• Officer • Chief R&D Officer
10b5-1 SellΔOwn -15.3%
2026-01-20
$137,936
|
||||||
| NKTR |
NEKTAR THERAPEUTICS
|
Officer • Chief R&D Officer
10b5-1 SellΔOwn -15.3%
|
2026-01-20 | $137,936 | S | Form 4 |
| NKTR |
NEKTAR THERAPEUTICS
|
CEO
Sell to Cover
|
2025-11-25 | $119,796 | S | Form 4 |
|
NKTR
S
NEKTAR THERAPEUTICS
Wilson Mark Andrew
• Officer • Chief Legal Officer
Sell to Cover
2025-11-25
$34,196
|
||||||
| NKTR |
NEKTAR THERAPEUTICS
|
Officer • Chief Legal Officer
Sell to Cover
|
2025-11-25 | $34,196 | S | Form 4 |
|
NKTR
S
NEKTAR THERAPEUTICS
Zalevsky Jonathan
• Officer • Chief R&D Officer
Sell to Cover
2025-11-25
$62,802
|
||||||
| NKTR |
NEKTAR THERAPEUTICS
|
Officer • Chief R&D Officer
Sell to Cover
|
2025-11-25 | $62,802 | S | Form 4 |